Daliborka Bursac

Prof. Dr. Daliborka Bursac


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2024 in Current Oncology
Verified
Journal Article
Open access
PDF file
Tomi KovacevicTomi Kovacevic
Tomi Kovacevic
BZBojan Zaric
Bojan Zaric
JMJelena Djekić Malbaša Djekić Malbaša
Jelena Djekić Malbaša Djekić Malbaša
DBDarijo Bokan
Darijo Bokan
BNBorislava Lazar Nikolin
Borislava Lazar Nikolin
DMDragana Maric
Dragana Maric
Background and Objectives: Death is an unavoidable experience in any person’s life and affects not only the dying person but also their caregivers. The dying process has been displaced from homes to health care facilities in the majority of cases. Facing death and dying has become an everyday life of health care professionals (HCP), especially in palliative care (PC) settings. This study aimed to investigate the death attitudes among HCPs in Serbia. Materials and Methods: The Serbian version of the Death Attitude Profile-Revised (DAP-RSp) was used as a measurement instrument. Results: The average age of the 180 included participants was 42.2 ± 9.9 years; the majority were females (70.0%), with more than 10 years of working experience (73.0%), physicians (70.0%) and those working in a non-oncological (non-ONC) field (57.78%). The mean total score of DAP-RSp was 124.80 ± 22.44. The highest mean score was observed in the neutral acceptance dimension (NA) (5.82 ± 0.90) and lowest in the Escape acceptance (EA) (2.57 ± 1.21). Higher negative death attitudes were reported among nurses compared to physicians (p = 0.002). Statistically significant differences were observed in the fear of death (FD) and death avoidance (DA) domains, favoring PC specialists and oncologists (p = 0.004; p = 0.015). Physicians working in Oncology (ONC) showed lower FD values (p = 0.001) compared to non-ONC departments. Conclusions: Attitudes toward death among HCPs are of great importance for the well-being of both HCPs and patients. Negative attitudes can lead to deficient care. The fear of death is highly represented among Serbian HCPs working in non-ONC fields, including both nurses and physicians. This study emphasizes the need for further research to comprehensively explore and understand HCPs’ attitudes toward death. This research highlights the need for the development of an educational curriculum across all levels of medical education, aimed at overcoming the fear of death and enhancing coping strategies, which will improve the care for patients diagnosed with terminal illnesses.

1 November 2024 in Cancers
Verified
Journal Article
Open access
PDF file
MKMilica Kontić
Milica Kontić
FMFilip Marković
Filip Marković
NNNikola Nikolic
Nikola Nikolic
NSNatalija Samardžić
Natalija Samardžić
GSGoran Stojanovic
Goran Stojanovic
MSMihailo Stjepanovic
Mihailo Stjepanovic
Immune checkpoint inhibitors (ICIs) like atezolizumab have improved outcomes in advanced non-small cell lung cancer (NSCLC) patients, especially in the second-line setting after progression on platinum-based chemotherapy. However, access to ICIs remains limited in many developing nations. This study evaluated the efficacy of atezolizumab as a second-line versus later-line treatment for advanced NSCLC patients in Serbia. Methods: This retrospective study involved 147 advanced NSCLC patients treated with atezolizumab following progression on prior platinum-based chemotherapy at two academic centers in Serbia. Data on demographics and clinical, pathological, and molecular characteristics were collected. Median progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method, and multivariable Cox proportional hazards regression identified outcome predictors. Results: The median PFS was 7.13 months, and median OS was 38.6 months. The overall response rate (ORR) was 15%, with a disease control rate (DCR) of 57.9%. No significant PFS differences were observed between patients treated with atezolizumab in the second line versus later lines. Patients with good performance status (ECOG 0–1) had significantly better PFS compared to those with poorer status (12.03 vs. 1.63 months, p < 0.0001). Conclusions: Atezolizumab is effective in both second-line and later-line settings for advanced NSCLC, particularly in patients with good performance status. This highlights the importance of patient selection based on performance status, as well as the need for wider access to ICIs in resource-limited regions.

1 January 2022 in Vojnosanitetski Pregled
Verified
Journal Article
Open access
PDF file
DBDaliborka Bursac
Daliborka Bursac
BZBojan Zaric
Bojan Zaric
DBDarijo Bokan
Darijo Bokan
Tomi KovacevicTomi Kovacevic
Tomi Kovacevic
VSVladimir Stojsic
Vladimir Stojsic
Goran M. StojanovicGoran M. Stojanovic
Goran M. Stojanovic
Background/Aim: The COVID-19 pandemic has multiple impacts on the management of cancer patients. Treatment of malignancies, including chemotherapy, targeted therapy, immunotherapy and radiotherapy, can suppress the immune system and lead to the development of severe complications of COVID-19 infection. The aim of this study was to determine the mortality of lung cancer (LC) patients, in whom the COVID-19 infection was confirmed during active antitumor treatment. Methods: This retrospective study was conducted at the Institute for Pulmonary Diseases of Vojvodina. All patients included in the study underwent active anticancer treatment at the time of diagnosis of COVID-19. SARS-CoV-2 infection was determined with polymerase chain reaction test (PCR). Patient data were collected using the institutional database and observed period was from November 20, 2020 to June 5, 2021. Statistical analysis of the derived patient’s data using the multivariate and univariate testing. Results: Out of total 828 observed COVID-19 hospitalized patients 81 were LC patient on active antitumor treatment. Patients were predominantly male (67.9%), smokers (55.6%), 66.47 years old (range 43-83). Majority of patients (50.6%) were Eastern Cooperative Oncology Group performance status (ECOG PS) 1 and 83.9% had at least one comorbidity. The most common comorbidities were arterial hypertension (66.7%), chronic obstructive pulmonary disease (COPD) (28.4%) and diabetes (21%). Obesity, congestive heart failure and other cardiovascular diseases were present in 11%, 6.2% and 7.4% of patients. The most common was adenocarcinoma (33.3%), followed by squamous (30.9%) and small-cell lung cancer (24.7%). Predominantly 63% of the patients were in stage III of disease and 33.3% were in stage IV. Metastases were most commonly present in the contralateral lung/pleura (14.8%), brain (6.2%), bone (3.7%) and liver (3.7%). Systemic anticancer therapy was applied in 37/81 patients (45.6%), chest radiotherapy in 35/81 (43.2%), concurrent chemoradiotherapy in 1/81 (1.2%) and other types of radiotherapy in 8/81 patients (9.87%). The most common forms of systemic therapy were chemotherapy (35.8%), immunotherapy (7.4%) and targeted therapy (2.4%) patients. Most common chemotherapy was cisplatin-based regiment applied in 34.6% of patients. The mortality from COVID-19 was 19.8%. The statistically significance in relation to the type of treatment was not observed (p = 0.973). Statistical significance was observed between mortality and ECOG PS (p = 0.011). Conclusions: LC patients are dependent on antitumor treatment and at the same time highly susceptible to potential infection. In this study we did not find statistically significant differences in mortality related to the type of antitumor treatment in COVID-19 positive LC patients. Further detailed research on larger scale is needed to be performed in order to explore the effects of SARS-CoV-2 on cancer patients. All possible methods of protection against SARS-CoV-2 virus should be performed in order to minimize the risk of infection in all but especially in immunocompromised cancer patients.

10 May 2021 in Case Reports in Oncology
Verified
Journal Article
Open access
PDF file
DBDaliborka Bursac
Daliborka Bursac
BZBojan Zaric
Bojan Zaric
Tomi KovacevicTomi Kovacevic
Tomi Kovacevic
VSVladimir Stojsic
Vladimir Stojsic
AVAnastasios Vagionas
Anastasios Vagionas
VSVanesa Sekerus
Vanesa Sekerus
Traditionally, tissue availability from rebiopsy is a prerequisite for adequate sequencing of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in therapy for advanced-stage lung cancer. Tissue biopsy truly is the gold standard for genetic analyses, but in some cases, such as with inadequate localization of the lesion or a patient’s inadequate performance status, comorbidities, or unwillingness to undergo an invasive procedure, liquid biopsy-based ctDNA analysis can be a noninvasive alternative approach. However, in some cases the gold standard might not shine that much. It is known that tumor heterogeneity or an inadequate amount of tissue might significantly interfere with the results of testing. In this paper, we present cases of patients with a negative tissue biopsy but a positive liquid biopsy which identified coexisting T790M mutation. These results enabled adequate sequencing and treatment with third-line EGFR-TKIs. Such possibilities stress the need to individualize testing for driver mutations in cases where it is clinically highly indicated.

29 October 2025 in Healthcare
Verified
Journal Article
Open access
PDF file
JMJelena Djekić Malbaša Djekić Malbaša
Jelena Djekić Malbaša Djekić Malbaša
Tomi KovacevicTomi Kovacevic
Tomi Kovacevic
MVMarija Vukoja
Marija Vukoja
DBDaliborka Bursac
Daliborka Bursac
DBDarijo Bokan
Darijo Bokan
BZBojan Zaric
Bojan Zaric
Background/Objectives: Early detection of lung cancer through low-dose computed tomography (LDCT) significantly improves patient outcomes. Identifying predictors of positive baseline LDCT findings can optimize screening programs and cost-effectiveness, particularly in regional settings. Methods: We conducted a retrospective analysis of baseline LDCT screenings performed in 2024 at three sites in Vojvodina, Serbia. Eligible participants were adults aged 50–74 years with a significant smoking history. Lung nodules were evaluated using the Lung-RADS system. Sociodemographic, clinical, and nodule-related variables, as well as radiologist experience (>10 vs. <10 years), were assessed. Multivariable logistic regression identified independent predictors of positive LDCT outcomes (Lung-RADS 3, 4A, 4B, 4X). Results: Overall, 17.6% (613/3479) of participants had positive baseline LDCT findings. Multivariable analysis showed that nodule type (semi-solid: OR = 4.01, 95% CI: 1.46–11.01; solid: OR = 8.86, 95% CI: 4.53–17.32), nodule morphology (smooth: OR = 0.42, 95% CI: 0.22–0.81; perifissural: OR = 0.16, 95% CI: 0.08–0.33; endobronchial: OR = 47.99, 95% CI: 12.35–186.58), nodule diameter (OR = 1.83 per mm, 95% CI: 1.71–1.96), presence of COPD (OR = 1.95, 95% CI: 1.23–3.08), age (OR = 1.02 per year, 95% CI: 1.00–1.04), and radiologist <10 years working experience (OR = 1.47, 95% CI: 1.23–3.08) were independent predictors of positivity. Conclusions: Baseline LDCT positivity is influenced by nodule characteristics, patient sociodemographic and clinical factors, and radiologist experience. These findings can inform targeted screening strategies in high-risk populations.

8 March 2024 in Medicina
Verified
Journal Article
Open access
PDF file
NLNensi Lalic
Nensi Lalic
Marko BojovićMarko Bojović
Marko Bojović
OIOlivera Ivanov
Olivera Ivanov
JLJelena Licina
Jelena Licina
SPSpasoje Popevic
Spasoje Popevic
Bojan PetrovicBojan Petrovic
Bojan Petrovic
Background and Objectives: Advanced lung cancer is usually manifested by endoluminal tumor propagation, resulting in central airway obstruction. The objective of this study is to compare the high dose rate brachytherapy treatment outcomes in non-small-cell lung cancer (NSCLC) depending on the treatment planning pattern—two-dimension (2D) or three-dimension (3D) treatment planning. Materials and Methods: The study was retrospective and two groups of patients were compared in it (a group of 101 patients who underwent 2D planned high-dose-rate endobronchial brachytherapy (HDR-EBBT) in 2017/18 and a group of 83 patients who underwent 3D planned HDR-EBBT between January 2021 and June 2023). Results: In the group of 3D planned brachytherapy patients, there was a significant improvement in terms of loss of symptoms of bronchial obstruction (p = 0.038), but no improvement in terms of ECOG PS (European Cooperative Oncology Group Performance Status) of the patient (p = 0.847) and loss of lung atelectasis (if there was any at the beginning of the disease) (p = 0.781). Two-year overall survival and time-to-progression periods were similar for both groups of patients (p = 0.110 and 0.154). Fewer treatment complications were observed, and 91.4% were in 3D planned brachytherapy (BT) patients. Conclusions: Three-dimensionally planned HDR-EBBT is a suggestive, effective palliative method for the disobstruction of large airways caused by endobronchial lung tumor growth. Independent or more often combined with other types of specific oncological treatment, it certainly leads to the loss of symptoms caused by bronchial obstruction and the improvement of the quality of life of patients with advanced NSCLC. Complications of the procedure with 3D planning are less compared to 2D planned HDR-EBBT.